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Abstract 7-Deazaxanthine (7-DX) was recently identified as
the first purine derivative with pronounced inhibitory activity
against Escherichia coli thymidine phosphorylase (TP) and
angiogenesis. In order to ‘freeze’ the enzyme in an open, inactive
conformation, a novel multi-substrate analogue inhibitor of TP,
containing an alkyl phosphonate moiety covalently linked to 7-
DX, was synthesized. The prototype compound TP65 (9-(8-
phosphonooctyl)-7-deazaxanthine) (at 250 WM) completely
inhibited TP-induced formation of microvascular sprouts from
endothelial cell aggregates in a three-dimensional fibrin gel. In
the chick chorioallantoic membrane assay, TP caused a dose-
dependent stimulation of angiogenesis, which was completely
inhibited by 250 nmol TP65. This dose proved to be non-toxic for
the developing chick embryo. TP65 thus emerges as a potent and
specific inhibitor of TP and TP-induced angiogenesis, which
opens new perspectives for multi-substrate analogue inhibitors of
TP as potential anti-cancer agents and as inhibitors of
angiogenesis and of diseases with enhanced expression of
TP. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Angiogenesis, the process of generating new capillary blood
vessels from pre-existing vessels, is a fundamental process in
reproduction [1,2] and wound healing [2]. In these conditions,
neovascularization is tightly regulated. Unregulated angiogen-
esis may lead to several angiogenic diseases [3] and is thought
to be indispensable for solid tumor growth and metastasis [4].
The construction of a vascular network requires di¡erent se-
quential steps including the release of proteases from ‘acti-
vated’ endothelial cells with subsequent degradation of the
basement membrane, endothelial cell migration and prolifer-
ation, and di¡erentiation into mature blood vessels. These
processes are mediated and modulated by a wide range of
angiogenic inducers, including growth factors, chemokines
and enzymes [2].
Platelet-derived endothelial cell growth factor/thymidine
phosphorylase (TP) is an enzyme with important angiogenic
properties. TP has been shown to stimulate endothelial cell
migration in vitro and angiogenesis in vivo [5^8]. The enzy-
matic activity of TP was found to be crucial for its angiogenic
e¡ect [9]. TP induces the reversible phosphorolysis of pyrim-
idine deoxynucleosides to 2-deoxyribose 1-phosphate and
their respective pyrimidine bases [10]. Recent observations
suggest that 2-deoxyribose 1-phosphate, which is a strongly
reducing sugar, generates oxygen radical species, which may
induce the secretion of oxidative stress-responsive angiogenic
factors, like vascular endothelial growth factor, interleukin-8
and matrix metalloproteinase-1 [11].
TP is overexpressed in many solid tumors and TP levels
correlate well with microvessel density in breast [12], ovarian
[13], colorectal [14], endometrial [15] and oesophageal [16]
cancers, pointing to a role for this enzyme in tumor vascular-
ization. Moreover, TP has recently been shown to inhibit
tumor cell apoptosis [14,17]. Therefore, there is an anti-cancer
potential for potent and speci¢c TP inhibitors. Among the
¢rst inhibitors of TP that have been described, 6-aminothy-
mine and 6-amino-5-bromouracil are the most potent [18].
Based on the structure of Escherichia coli TP [19], which
shows 40% sequence identity with human TP, we recently
designed and synthesized the ¢rst purine derivative (7-deazax-
anthine, 7-DX) with inhibitory activity against E. coli TP [20].
We used 7-DX as a lead compound to develop a novel type
of multi-substrate analogue inhibitor of TP [21,22]. The
prototype compound (9-(8-phosphonooctyl)-7-deazaxanthine,
TP65) contains an alkyl phosphonate moiety, covalently
linked to 7-DX. We proved that this novel TP inhibitor was
able to interact at both the phosphate binding site and the
nucleoside binding site, thus ‘freezing’ the enzyme in an open,
inactive conformation [22].
In the present study, we describe the marked inhibitory
activity of the novel multi-substrate analogue TP inhibitor
(TP65) against angiogenesis induced by TP in both cell culture
and in the chorioallantoic membrane (CAM) assay.
2. Materials and methods
2.1. Compounds
7-DX and the multi-substrate analogue inhibitor TP65 were synthe-
sized as described [20,21]. For the chemical structures of these com-
pounds, see Fig. 1. E. coli TP (1030 U/ml) was obtained from Sigma
(St. Louis, MO, USA).
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2.2. Cells
Mouse brain endothelial (MBE) cells, provided by Dr. M. Presta
(Brescia, Italy) were maintained in Dulbecco’s modi¢ed minimum
essential medium (DMEM; Gibco, Life Technologies, Rockville,
MD, USA) supplemented with 2 mM glutamine (Gibco) and 10%
fetal calf serum (Integro, Zaandam, The Netherlands).
2.3. Puri¢cation of glutathione-S-transferase (GST)-TP
The E. coli TP gene was expressed in E. coli as a GST fusion
protein as follows. The TP gene was isolated from genomic DNA
of E. coli K12 and subcloned in the pGEM-T vector (Promega, Mad-
ison, WI, USA). The forward (5P-AAG AAT TCT TTC TCG CAC
AAG AAA TTA TTC G) and reverse (5P-AAG TCG ACT TAT TCG
CTG ATA CGG CG) primers (Gibco, Paisley, UK) introduce an
EcoRI and SalI site, respectively. The TP gene was subsequently
cloned between the EcoRI and SalI sites of the pGEX-5X-1 vector
(Amersham Pharmacia Biotech, Uppsala, Sweden). The resulting plas-
mid vector (pGEX-5X-1-TP) was checked by automated £uorescence
sequencing (ALFexpress, Amersham Pharmacia Biotech) and trans-
fected into E. coli BL21(DE3)pLysS. Bacteria were grown overnight
at 37‡C in 2YT medium containing ampicillin (100 Wg/ml) and chlor-
amphenicol (40 Wg/ml), and then diluted 1:10 in fresh medium. After
further growth of the bacteria at 27‡C (for 1 h), isopropyl-L-D-thio-
galactopyranoside (Sigma) was added to a ¢nal concentration of 0.1
mM to induce the production of the GST-TP fusion protein. After 15
h of further growth at 27‡C, cells were pelleted (6000Ug for 10 min at
4‡C) and resuspended in lysis bu¡er (50 mM Tris, pH 7.5, 1 mM
dithiothreitol, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 0.1
mM phenylmethylsulfonyl£uoride (PMSF) and 0.15 mg/ml lysosyme).
Bacterial suspensions were homogenized and lysed by means of a
‘French Pressure cell press’, and ultracentrifuged (20 000Ug for 15
min at 4‡C). GST-TP was puri¢ed from the supernatant using Glu-
tathione Sepharose 4B (Amersham Pharmacia Biotech) as described
by the supplier. Brie£y, a 50% slurry of Glutathione Sepharose was
added to the bacterial supernatant (1.5 ml/1.5 l of broth), incubated
for 30 min at 4‡C, and then washed three times with 10 bed volumes
(7.5 ml) of lysis bu¡er without lysosyme and PMSF. Bound proteins
were eluted in 50 mM Tris (pH 8.0) containing 0.1% Triton X-100 and
10 mM glutathione. Protein content of the puri¢ed fractions was
assessed using Bradford reagent (Sigma).
2.4. Endothelial cell-sprouting assay
Fibrinogen (5 mg/ml) was dissolved in DMEM/HAM12 medium.
Then, MBE cell aggregates, prepared on agarose-coated plates (to
prevent spreading of the cells), as described previously [23], were
resuspended in the ¢brinogen solution, and clotting was initiated by
the addition of thrombin (500 mU/ml). The mixture was transferred
into 24-well plates and allowed to gelify at 37‡C. Cell aggregates were
maintained for 3 days in DMEM/HAM12 medium containing the test
compounds, and the formation of endothelial cell sprouts was eval-
uated daily.
2.5. CAM assay in fertilized chicken eggs
The in vivo CAM angiogenesis model was performed as described
by Maragoudakis et al. [24]. Fertilized eggs were incubated for 3 days
at 37‡C when 3 ml of albumin was removed (to detach the shell from
the developing CAM) and a window was opened on the eggshell
exposing the CAM. The window was covered with cellophane tape
and the eggs were returned to the incubator until day 9 when the test
compounds were applied. The compounds were placed on sterile plas-
tic discs (Ò 8 mm) which were allowed to dry under sterile conditions.
A solution of cortisone acetate (100 Wg/disc, Sigma) was added to all
discs in order to prevent an in£ammatory response. A loaded and
dried control disc was placed on the CAM 1 cm away from the disc
containing the test compound(s). Next, the windows were covered and
the eggs incubated until day 11 when angiogenesis was assessed. At
day 11, the eggs were £ooded with 10% bu¡ered formalin (Janssen
Chimica, Geel, Belgium), the plastic discs were removed and the eggs
were kept at room temperature for 2 h. A large area around the discs
was cut o¡ and placed on a glass slide, and the vascular density index
was measured by the method of Harris-Hooker et al. [25]. Brie£y, a
grid containing three concentric circles of 4, 5 and 6 mm diameter was
positioned on the surface of the CAM previously covered by the disc.
Next all vessels intersecting the circles were counted. A two-tailed
paired Student’s t-test was used to assess the signi¢cance of the ob-
tained results.
2.6. Inhibitory e¡ect of TPase inhibitors on blood vessel formation
induced by exogenous TPase
Angiogenesis in the CAM assay was stimulated by the addition of a
commercial preparation of pure E. coli TP. Di¡erent amounts of the
enzyme (20, 10, 5 or 1 U), spotted on discs, were applied onto the
CAM. After 2 days, the number of blood vessels under each disc were
counted and compared with discs that contained only phosphate-bu¡-
ered saline (PBS) (or dimethyl sulfoxide, DMSO). To evaluate the
e¡ect of the inhibitors on TPase-induced blood vessel formation,
TP65 and 7-DX (250 nmol) were spotted together with the enzyme
(10 U) on the discs. Determination of blood vessel formation was
performed after 2 days (i.e. day 11).
2.7. Cytostatic and cytotoxic e¡ect of TP-65 and 7-DX in
endothelial cell cultures
Endothelial cells from sponge implants (SIEC) [26] were seeded at
two di¡erent cell densities (10 000 or 20 000 cells) per well of a gelatin-
coated 96-well microtiter plate and exposed to 250, 100, 50, 20 and
5 WM of the test compounds in DMEM, supplemented with 1 mM
L-glutamine, 1% non-essential amino acids, 1 mM sodium pyruvate
and 20% FCS. Freshly prepared endothelial cell growth supplement
and heparin at 100 Wg/ml was also added to the medium. After 4 days
of incubation, cells were trypsinized and counted by a Coulter counter
(Harpenden Hertz, UK) or stained with trypan blue to reveal poten-
tial cellular toxicity of the compounds.
3. Results
3.1. Inhibition of tube formation in vitro by TP65 and 7-DX
TP65 and 7-DX were evaluated for their capacity to a¡ect
the sprouting of endothelial cell sprouts in vitro. In this assay,
endothelial cell aggregates are embedded into a ¢brin gel in
the presence of an angiogenic stimulus, which induces the
formation of endothelial cell sprouts. Accordingly, MBE cell
aggregates were incubated in the presence of 100 U/ml of
recombinant E. coli GST-TP. After 2 days of incubation,
MBE cells started to invade the gel and to develop radially
growing sprouts (Fig. 2B). TP65 (at 250 nM) and 7-DX (at
250 nM) completely inhibited the formation of endothelial
sprouts induced by GST-TP (Fig. 2C for TP65 and data not
shown for 7-DX).
3.2. Inhibitory e¡ect of TP65 on neovascularization in the
CAM assay
Based on our previous cell culture observations, we then
evaluated the e¡ect of TP65 on angiogenesis in the CAM
assay. The in vitro tube formation experiment was performed
with E. coli TP, puri¢ed as a fusion protein with GST. In
order to rule out the possibility that GST might in£uence
the activity of TP or TP65, we used a commercial preparation
of pure E. coli TP to stimulate angiogenesis in the CAM
assay.
Fig. 1. Structural formulae of 7-DX and the multi-substrate ana-
logue inhibitor TP65.
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In a ¢rst set of experiments, the e¡ect of di¡erent TP
amounts on blood vessel formation was investigated. After
2 days of exposure, TP caused a dose-dependent formation
of new blood vessels that developed radially towards the disc
containing the angiogenic stimulus (Fig. 3A). 10 U of TP
induced angiogenesis in all CAMs tested, with an average
stimulation of 40% þ 8 (P6 0.05, Fig. 3A^C). TP was clearly
stimulatory at 5 U/disc (16% þ 11, P6 0.05), although only
60% of the CAMs showed an increase in the number of blood
vessels (Fig. 3B). Application of 20 U of TP onto the CAM
resulted in in£ammation and the appearance of blood clots,
which made morphological evaluation of the vessels virtually
impossible. Therefore, 10 U of TP was considered to be
the optimal dose to evaluate the activity of test compounds
(i.e. TP65 and the reference compound 7-DX) in the CAM
assay.
In a second set of experiments, TP65 and 7-DX were
applied onto the CAM of fertilized chicken eggs at 50 and
250 nmol. At least 10 eggs were scored for each inhibitor
concentration in two independent experiments. TP65 mark-
edly prevented blood vessel formation, induced by TP, on
the CAM during a 2-day exposure time period. At 250
nmol of TP65, a complete inhibition of TP-induced blood
vessel formation was observed, i.e. 40% stimulation by TP
in the absence of TP65 versus 5% inhibition by TP in the
presence of TP65 (P6 0.001, Figs. 4A and 5B), and only
8% of the CAMs displayed an increase in the number of blood
vessels (versus 100% in the CAMs exposed to TP alone, Fig.
4B). At 50 nmol of TP65, stimulation of angiogenesis by TP
was not inhibited. 7-DX, dissolved in DMSO, was included as
a reference compound. Although DMSO alone diminished the
angiogenic e¡ect of TP to 24% þ 9 (Fig. 4C), addition of 250
nmol of 7- DX further reduced neovascularization to 6% þ 11
(P6 0.05, Fig. 4C), with 65% of the CAMs showing stimula-
tion (Fig. 4D). TP65 thus proved to be a markedly better
inhibitor of TP-induced angiogenesis in the CAM assay
than 7-DX.
3.3. Cytostatic activity of TP65 and 7-DX against
endothelial cells
TP65 and 7-DX have been evaluated for their anti-prolifer-
ative and cytotoxic activity against endothelial (SIEC) cell
cultures. At 250, 100 and 50 WM, the compounds did not
Fig. 2. E¡ect of TP65 on tube formation in vitro. Aggregates containing 25 000 MBE cells were suspended in a ¢brinogen gel and incubated in
DMEM/HAM12 medium. Control cultures showed migration of endothelial cells after 3 days (A). Addition of TP resulted in the formation of
microvascular tubes (B). The angiogenic activity of TP was completely inhibited by the addition of 250 nmol TP65 (C). Original magni¢cation:
40U.
Fig. 3. Stimulation of angiogenesis by TP in the CAM assay. At
day 9 of incubation, discs containing either TP or PBS were applied
onto the CAM. At day 11, the blood vessels under each disc were
counted and the percentage of stimulation (A), the percentage of
the CAMs that show stimulation (B), and the number of blood ves-
sels (C), were determined (*P6 0.05).
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inhibit endothelial cell proliferation. The cell numbers ob-
tained after 4 days of drug exposure at the indicated com-
pound concentrations were not signi¢cantly di¡erent from
drug-free control cultures. Also, trypan blue dye exclusion
revealed s 95% viability at 250 and 100 WM of both test
compounds upon a 3-day exposure time period.
4. Discussion
7-DX was identi¢ed as the ¢rst purine derivative with in-
hibitory activity against TP [20]. The compound may mimic
thymine in the TP active site since it contains the CO^NH^
CO functional entity of the pyrimidine ring, while the C7NC8
moiety of the pyrrole ring of 7-DX corresponds to the
5-methyl part of the thymine molecule. 7-DX was used as a
lead compound to design more potent purine-based multi-sub-
strate TP inhibitors, such as TP65 [21,22]. TP65 is a multi-
substrate inhibitor, able to concomitantly interact at the phos-
phate binding site and the nucleoside binding site, with the
purpose of immobilizing the enzyme in an open, inactive con-
formation [21,22].
TP65 completely abrogated the formation of vascular
sprouts from endothelial cell aggregates in vitro. In the
CAM assay, both the percentage of CAMs in which TP
Fig. 4. Inhibition of TP-induced angiogenesis in the CAM assay by TP65 and 7-DX. At day 9 of incubation, discs containing either TP (A^D),
TP plus TP65 (A, B) or TP plus 7-DX (C, D) were applied onto the CAM. At day 11, the percentage of the CAMs that show stimulation
(B, D) and the percentage of stimulation (A, C), were determined (*P6 0.05).
Fig. 5. E¡ect of TP65 on TP-induced angiogenesis in the CAM assay. At day 9 of incubation, discs containing either TP or TP plus TP65
were applied onto the CAM. Two days later, new blood vessels developed radially towards the disc containing TP (A), whereas no increase in
the number of blood vessels or a change in their orientation could be observed when the disc contained TP plus TP65 (B).
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causes stimulation of angiogenesis and the increase in the
number of blood vessels were determined. A maximum stim-
ulation of 40% could be achieved by 10 U of E. coli TP.
However, the method of Harris-Hooker [25] does not distin-
guish between newly formed microvessels (after application of
the discs on the CAM) and those that were already present at
day 9 and, therefore, may underestimate the stimulatory ac-
tivity of TP.
In the CAM assay, 7-DX partially inhibited TP-induced
angiogenesis, under the experimental conditions where the
novel multi-substrate analogue inhibitor TP65 completely ab-
rogated the formation of TP-induced neovascularization of
the chick CAM. Thus, angiogenesis induction by TP was
completely inhibited by the addition of 250 nmol of TP65.
Furthermore, TP65 did not cause embryo death or in£amma-
tion of the CAM at the doses used in this study, nor did it
inhibit the proliferation of endothelial cells in vitro, which
clearly indicates that the inhibition of TP-induced angiogene-
sis is a speci¢c, non-toxic e¡ect.
Angiogenesis is induced by a variety of molecules, many of
them are peptide growth factors, which interact with two
types of receptors: low a⁄nity receptors or heparin-contain-
ing glycosaminoglycans and high a⁄nity tyrosine kinase re-
ceptors [2]. Heparin binding occurs via basic amino acid res-
idues in the growth factor molecule. All known inhibitors of
these growth factors either disrupt the binding of the growth
factor to heparin or to the tyrosine kinase receptor. In con-
trast, TP is not a growth factor, i.e. it does not stimulate
endothelial cell proliferation, and does not interact with any
receptor. In fact, the angiogenic action of TP depends on its
enzymatic activity and the subsequent release of 2-deoxy-D-
ribose [3,7], which is the molecule responsible for the angio-
genic e¡ect of TP [27]. Thus, the mechanism of action and the
structure of TP65 is totally di¡erent from those of heparin-
binding growth factors. Since TP65 has been speci¢cally de-
signed as a multi-substrate inhibitor, based on the structure of
E. coli TP, and since this compound was proven to concom-
itantly interact with two di¡erent sites of the TP enzyme [22],
it is very unlikely that this TP inhibitor also a¡ects the activity
of angiogenic growth factors.
Since both GST-TP and commercially available TP are pro-
duced in E. coli, they may contain endotoxins. However, we
are convinced that the angiogenic activity of GST-TP and TP
is not due to endotoxin (known to be an angiogenic agent)
contamination because of a lack of angiogenic activity has
been reported by Moghaddam et al. [8] for a mutated TP
enzyme also produced in E. coli. Moreover, the angiogenic
activity of GST-TP and TP in the present study can be com-
pletely inhibited by the TP inhibitor TP65, which would be
impossible if blood vessel formation was caused by contami-
nating endotoxin.
Taken together, TP65 emerges as a highly speci¢c and non-
toxic TP inhibitor. Although the in vivo activity of TP65 still
has to be established, our ¢ndings open new perspectives for
the use of this novel type of multi-substrate analogue inhibitor
in the treatment of cancer and various other angiogenic dis-
eases that overexpress TP, such as rheumatoid arthritis [27],
psoriasis [28], atherosclerosis [29] and gastric ulcers [30]. In
addition, TP65 may also potentiate the activity of several anti-
viral agents (i.e. (E)-5-(2-bromovinyl)-2P-deoxyuridine, 5-iodo-
2P-deoxyuridine) and anti-tumor agents (i.e. 5-£uoro-2P-de-
oxyuridine) that are susceptible to inactivation (hydrolysis)
by TP [31,32].
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